Ionis–Otsuka ALS Success and Boehringer’s Potential $1B Oncology Deal on September 23, 2026 Amyotrophic Lateral Sclerosis Antisense Oligonucleotides Boehringer Ingelheim Envisagenics FUS-ALS Ionis Pharmaceuticals Neoplasms Otsuka Pharmaceutical RNA Splicing Solid Neoplasm ulefnersen +